Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Veritas In Silico Inc. ( (JP:130A) ) has provided an announcement.
Veritas In Silico Inc. has announced its strategy to transform into a specialty pharmaceutical company by enhancing its aibVIS platform with AI technologies to accelerate drug discovery. The company plans to expand its intellectual property portfolio and form strategic alliances to secure new revenue opportunities, aiming to increase its corporate value through a hybrid business model that combines platform-based business with high-value pipeline development.
More about Veritas In Silico Inc.
Veritas In Silico Inc. operates in the pharmaceutical industry, focusing on mRNA-targeted drugs. The company leverages its advanced drug discovery platform, aibVIS, which integrates AI modules to enhance drug research and development. Veritas In Silico aims to expand its intellectual property and form strategic alliances to broaden its market focus into areas like agrochemicals and medical devices.
Average Trading Volume: 39,315
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.19B
For an in-depth examination of 130A stock, go to TipRanks’ Overview page.